Gynecologic oncology is a surgical subspecialty focused on diagnosing and treating cancers of the female reproductive system. That includes cancers of the ovaries, uterus, cervix, vagina, vulva, and, rarely, the fallopian tubes. These specialists combine advanced surgical skills with deep knowledge of chemotherapy, radiation, and newer targeted treatments, making them the primary doctors who manage a patient’s cancer care from diagnosis through treatment and follow-up.
What a Gynecologic Oncologist Does
A gynecologic oncologist is not the same as a regular OB-GYN. While general gynecologists handle routine reproductive health, gynecologic oncologists have completed an additional three years of fellowship training specifically in cancer surgery, chemotherapy, and the biology of gynecologic tumors. Before that fellowship, they finish a full obstetrics and gynecology residency. They also must complete and defend a research thesis before graduating, which means their training blends hands-on surgical expertise with scientific rigor.
In practice, these doctors do things a general gynecologist typically cannot. They perform complex cancer surgeries that may involve removing tumors from multiple organs in the pelvis and abdomen. They determine which patients need chemotherapy or radiation and often coordinate that care directly. For many gynecologic cancers, a gynecologic oncologist serves as the quarterback of the entire treatment plan.
The Six Types of Gynecologic Cancer
The five main gynecologic cancers are cervical, ovarian, uterine, vaginal, and vulvar. A sixth type, fallopian tube cancer, is very rare. Each behaves differently, presents with different symptoms, and requires a distinct treatment approach.
Uterine cancer is the most common of the group in the United States, often caught relatively early because it causes abnormal bleeding. Ovarian cancer, by contrast, is harder to detect early and tends to be diagnosed at a more advanced stage, making it one of the deadlier gynecologic cancers. Cervical cancer has become increasingly preventable through HPV vaccination and regular screening, but it still requires specialist surgical care when it does occur. Vaginal and vulvar cancers are less common but can be complex to treat, particularly when they involve surrounding structures.
When You’d Be Referred to One
Most people see a gynecologic oncologist after a general gynecologist, primary care doctor, or imaging study raises a red flag. The Society of Gynecologic Oncology has published specific guidelines for when referral is appropriate, and the triggers vary by cancer type.
For ovarian concerns, referral is recommended when a pelvic mass is large (over 10 cm), complex, fixed, or present on both sides. Postmenopausal women with suspicious ovarian masses or elevated tumor markers should also be referred. In perimenopausal women, a CA-125 blood marker between 35 and 65 is associated with a 50 to 60 percent cancer risk, and levels above 65 in women over 50 carry a 98 percent specificity for malignancy. Young patients with a pelvic mass and elevated markers also warrant referral, as do girls who haven’t yet reached puberty if they need surgery for a pelvic mass.
For uterine cancer, any woman with a confirmed diagnosis of endometrial cancer or recurrent disease should see a gynecologic oncologist. Cervical cancer referrals happen when there’s a visible suspicious growth on the cervix, a Pap smear suggesting invasion, or a biopsy confirming it. For vulvar concerns, non-healing ulcers, areas of chronic pain or itching, pigment changes, or any suspicious mass should prompt a referral. Women with a family history of ovarian, breast, or related cancers and a suspicious pelvic mass are also flagged for specialist evaluation.
Gestational trophoblastic disease, a group of rare conditions related to abnormal pregnancy tissue, also falls under this specialty. Molar pregnancies, persistent trophoblastic disease, and choriocarcinoma all require a gynecologic oncologist’s expertise.
Surgical Treatment
Surgery is central to gynecologic oncology, and the procedures can range from straightforward to extremely complex. For ovarian cancer, the standard approach is cytoreductive surgery, where the goal is to remove as much visible tumor as possible. “Optimal” cytoreduction typically means reducing any remaining disease to less than 1 to 2 centimeters. Removing large tumor masses improves the effectiveness of chemotherapy afterward, because smaller residual tumors have better blood supply and are more vulnerable to drug treatment.
In advanced cases, these surgeries may go well beyond the reproductive organs. Surgeons sometimes need to remove portions of the bowel, spleen, liver, or bladder to eliminate all visible cancer. In one study of patients undergoing surgery for recurrent ovarian cancer, nearly half required additional organ resections beyond the tumor itself. This is precisely why the specialty exists: these operations demand a surgeon who understands both reproductive anatomy and the broader abdominal cavity, and who can make real-time decisions about how aggressively to operate based on what they find.
When ovarian cancer recurs after an initial remission, a second surgery (called secondary cytoreduction) may be offered. This surgery aims to extend survival rather than cure the disease, and the decision depends on factors like how long the remission lasted and how much tumor can realistically be removed.
Chemotherapy and Targeted Therapies
Gynecologic oncologists don’t just operate. They also manage drug-based treatments, often in coordination with medical oncologists. Platinum-based chemotherapy remains the backbone of treatment for ovarian cancer and is used in several other gynecologic cancers as well.
Over the past decade, targeted therapies have significantly expanded the treatment toolkit. One major class is drugs that block a DNA repair mechanism in cancer cells. These are used as maintenance therapy in advanced ovarian cancer, meaning patients take them after chemotherapy to keep the disease from coming back. Three of these drugs are now approved for patients with platinum-sensitive relapsed ovarian cancer regardless of whether they carry a BRCA gene mutation. For patients who do have BRCA mutations or other DNA repair deficiencies, the benefit tends to be even greater.
Anti-angiogenic drugs, which starve tumors by blocking the growth of new blood vessels, are also part of the standard toolkit for ovarian cancer. These are sometimes combined with DNA repair-targeting drugs for an additive effect.
Immunotherapy has made inroads as well. Immune checkpoint inhibitors, which essentially remove the “brakes” that cancer puts on the immune system, have been approved for certain endometrial cancers. Tumors with a specific genetic feature (called mismatch repair deficiency) respond particularly well. For endometrial cancers without that feature, a combination of an immune checkpoint inhibitor with an oral drug that blocks tumor blood vessel growth has been approved after initial treatment fails.
The Care Team Around You
Gynecologic cancer treatment rarely involves a single doctor working alone. At most cancer centers, care is delivered through a multidisciplinary team that meets regularly to discuss each patient’s case. The core team typically includes the gynecologic oncologist, a medical oncologist (who specializes in chemotherapy and drug treatments), and a radiation oncologist.
Beyond the physicians, patients often interact with a nurse navigator who helps coordinate appointments and guide them through the treatment process. Nutritionists, social workers, and research nurses round out the team, addressing everything from managing treatment side effects to emotional support to access to clinical trials. This structure exists because gynecologic cancers often require a combination of surgery, drugs, and radiation, and no single specialist covers all of those areas with equal depth.